...
首页> 外文期刊>Biochemical Pharmacology >Motilin and erythromycin-A share a common binding site in the third transmembrane segment of the motilin receptor.
【24h】

Motilin and erythromycin-A share a common binding site in the third transmembrane segment of the motilin receptor.

机译:胃动素和红霉素-A在胃动素受体的第三个跨膜片段中有一个共同的结合位点。

获取原文
获取原文并翻译 | 示例

摘要

The motilin receptor (MTLR) represents a clinically useful pharmacological target, as agonists binding to the MTLR have gastroprokinetic properties. In order to compare the molecular basis for interaction of the MTLR with motilin and with the non-peptide motilin agonist, erythromycin-A (EM-A), the negatively charged E119 located in the third transmembrane (TM3) region was mutated to D (E119D) and Q (E119Q), respectively, and changes in activity of the mutant receptors were verified. METHODS: Each mutant receptor was stably transfected in CHO-cells containing the Ca2+ indicator apo-aequorin. Receptor activation in response to motilin, EM-A and their analogues was assessed by Ca2+-luminescense. RESULTS: In the E119Q mutant, the Ca2+ response to motilin and EM-A was abolished while in the E119D mutant it was reduced with 62% (motilin) and 81% (EM-A). The pEC50 values were shifted from 9.65+/-0.03 to 7.41+/-0.09 (motilin) and from 6.63+/-0.12 to 4.60+/-0.07 (EM-A). Acetylation of the N-terminal amine groupas in [N-acetyl-Phe]1 mot (1-14), decreased the potency 6.3-fold (WT-MTLR) and 148-fold (E119D). Acetylation of EM-A enol ether induced a more pronounced shift in potency: 7943-fold (WT-MTLR) and 1413-fold (E119D). CONCLUSION: The comparable loss of affinity of the mutant receptors for motilin and EM-A indicate that these agonists both interact with the TM3 domain of the MTLR. The results with acetylated derivatives support an ionic interaction between E119 of the MTLR with the N+ of the desosamine sugar in EM-A, but not with the N+ of the free amine group in motilin.
机译:胃动素受体(MTLR)代表临床上有用的药理学靶标,因为与MTLR结合的激动剂具有胃肠动力学特性。为了比较MTLR与胃动素以及与非肽胃动素激动剂红霉素A(EM-A)相互作用的分子基础,将位于第三跨膜(TM3)区的带负电荷的E119突变为D( E119D)和Q(E119Q),并验证了突变受体的活性变化。方法:将每种突变受体稳定转染到含有Ca2 +指示剂载脂蛋白水母发光蛋白的CHO细胞中。通过Ca 2+-光敏性评估响应于胃动素,EM-A及其类似物的受体活化。结果:在E119Q突变体中,对胃动素和EM-A的Ca2 +响应被消除,而在E119D突变体中,其减少了62%(胃动素)和81%(EM-A)。 pEC50值从9.65 +/- 0.03变为7.41 +/- 0.09(胃动素),从6.63 +/- 0.12变为4.60 +/- 0.07(EM-A)。在[N-乙酰基-Phe] 1 mot(1-14)中,N末端胺基的乙酰化使效价降低了6.3倍(WT-MTLR)和148倍(E119D)。 EM-A烯醇醚的乙酰化诱导效力发生更明显的变化:7943倍(WT-MTLR)和1413倍(E119D)。结论:突变受体对胃动素和EM-A亲和力的可比损失表明,这些激动剂均与MTLR的TM3结构域相互作用。乙酰化衍生物的结果支持MTLR的E119与EM-A中去氨糖的N +之间的离子相互作用,而不支持胃动素中的游离胺基的N +之间的离子相互作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号